Document:

Security Agreement

 EXHIBIT 10.3 
 SECURITY AGREEMENT 
 This Security Agreement
is made and entered into this 12th day of February, 2009, by and between PRO-PHARMACEUTICALS, INC. (hereinafter referred to as “Borrower”)
and 10X FUND, L.P. (hereinafter referred to as “Lender”) as follows: 
 FOR VALUE RECEIVED, and in order to secure payment of any
and all indebtedness of the Borrower to the Lender, now existing or hereafter incurred, matured or unmatured, direct or contingent, including any extensions, renewals and substitutions thereof, the Borrower hereby grants to the Lender a security
interest in, all of Borrower’s furniture, fixtures, equipment, furnishings, leases and lease rights, supplies, inventory, accounts receivable, contract rights, general intangibles, patents, trade secrets, intellectual property of any and every
kind, goods and tangible personal property of every kind and nature, including additions, replacements, accessions and proceeds now and hereafter owned and acquired (hereinafter referred to as “Collateral”). 
 This Security Agreement secures the indebtedness of the Borrower as evidenced by that promissory note (“Promissory Note”) given by Borrower to
Lender of even date herewith in the Redemption Amount (as defined in the Promissory Note). This Security Agreement secures to Lender: (a) the payment of the Promissory Note and all renewals, extensions and modifications of the Promissory Note;
(b) the payment of all other sums, with interest, advanced to protect the security of this Security Agreement including all expenditures for taxes, insurance and repairs and maintenance of the Collateral; (c) the performance of
Borrower’s covenants and agreements under this Security Agreement and the Promissory Note; and (d) any other indebtedness of the Borrower to the Lender, whether now existing or hereafter incurred, matured or unmatured, direct or
contingent. 
 1. UCC FINANCING STATEMENT. A UCC Financing Statement covering the Collateral herein secured shall be filed for record
with the appropriate office in Massachusetts, as well as any notices required by the United States Patent and Trademark Office. 
 2.
PROMISSORY NOTE PAYMENTS. Borrower shall promptly pay when due the principal and interest on the debt evidenced by the Promissory Note and any late charges due under the Promissory Note. Unless applicable law provides otherwise, all payments
received by Lender shall be applied first to interest due on the indebtedness, second to the principal due on the indebtedness, and third to any late charges outstanding under the Promissory Note. 
 3. LIENS. Borrower shall pay all taxes, assessments, charges, fines and impositions attributable to the Collateral that may attain priority over
this Security Agreement, and all leasehold payment or ground rents, if any. Borrower shall pay these obligations on time directly to the person owed the payment. Borrower shall promptly furnish to Lender receipts evidencing the payments, if
requested by Lender. Borrower shall promptly discharge any lien which may have priority over this Security Agreement. If Lender determines that any part of the Collateral is subject to a lien which may attain priority over this Security Agreement
Lender may give Borrower a notice identifying the lien. Borrower shall satisfy the lien within ten (10) days of the giving of notice. The Borrower will defend the Collateral against all other claims or demands of all persons at any time
claiming any interest in the Collateral, when such claim is adverse to the rights of the Lender conveyed in this Agreement. 
  

 1 

 4. COMPLIANCE WITH LAWS. Borrower shall, at all times, fully comply with all local, State and
Federal laws, regulations, statutes or ordinances relating to the use of the Collateral and the operation of Borrower’s business. Any Hazardous Substance used by Borrower shall be stored, maintained, removed and disposed of in full compliance
with all local, State and Federal (EPA/EPD) laws, regulations, statutes or ordinances. “Hazardous Substances” as used herein means and includes, without limitation, petroleum products, flammable explosives, radioactive materials, asbestos
(or any material containing asbestos), polychlorinated biphenyls and any other hazardous, toxic, or dangerous waste, substances, or materials defined as such (or any similar term) for the purposes of any State or Federal laws. 
 5. TRANSFER OF COLLATERAL. The Borrower shall not, without written consent of the Lender, sell, contract to sell, lease, assign or dispose of any
interest of any kind in the Collateral, except for the sale of the Collateral in the normal course of business, until this Security Agreement and all debts secured hereby have been fully paid and satisfied. If all or any part of the Collateral, or
any interest in the Collateral, is sold or transferred, or if a beneficial interest in Borrower is sold or transferred, or if the Borrower’s business is sold, assigned or transferred without Lender’s prior written consent, Lender may, at
its option, require immediate payment in full of all sums secured by this Security Agreement. Notwithstanding the foregoing, Borrower shall provide written notice by certified mail to the Lender of any sale, assignment or transfer of any interest in
the Borrower’s business or the Collateral for so long as there are any debts outstanding from Borrower to Lender. 
 6. CHANGES IN
COLLATERAL. The Borrower will keep the Collateral separate and identifiable at the Borrower’s business premises and will not remove the Collateral from said location without the Lender’s written consent. The Borrower shall promptly
notify Lender in writing of any proposed change in the location or ownership of the Borrower’s business. The Borrower shall be allowed to improve or replace any portion of the Collateral with collateral of greater or equal value without prior
consent of the Lender. In the event Borrower does replace any Collateral with collateral of greater or equal value, Borrower shall not be obligated to give Lender any of the proceeds from the prior held collateral. 
 7. INSURANCE. Borrower shall maintain at all times fire, liability and other casualty insurance and any other insurance required, including theft,
to protect the Collateral and fully secure Borrower’s obligation to Lender. The Lender shall be named as an additional insured and loss payee and shall be provided with a Certificate of Coverage. Such insurance coverage may be reduced by
Borrower subsequent to the date of closing provided that said coverage is always at least equal to the amount of Borrower’s debt to Lender at that time. Such insurance shall be obtained from companies registered to transact business in the
State of Massachusetts and said policy shall be issued in the names of Lender and Borrower, as their respective interests may appear, and proof of coverage and copies of all related documents shall be delivered to Lender, upon Lender’s request,
but at least annually, until such time as all Borrower’s obligations to Lender are satisfied. 
 In the event Borrower fails to maintain the coverage
described above, Lender may, at Lender’s option, obtain coverage to protect Lender’s rights in the Collateral, and Borrower shall be required to pay to Lender the reasonable costs and expenses incurred by Lender in obtaining such coverage.

 In the event of loss, Borrower shall give prompt notice to the insurance carrier and Lender. Lender 

  

 2 

 
may make proof of loss if not made promptly by Borrower. Unless Lender and Borrower otherwise agree in writing, insurance proceeds shall be applied to
restoration or repair of the Collateral damaged, if the restoration or repair is economically feasible and Lender’s security is not lessened. If the restoration or repair is not economically feasible or Lender’s security would be lessened,
the insurance proceeds shall be applied to the sums secured by this Security Agreement, whether or not then due, with any excess paid to Borrower. If Borrower abandons the Collateral, or does not answer within ten (10) days after notice from
Lender that the insurance carrier has offered to settle the claim, then Lender may collect the insurance proceeds. Lender may use the proceeds to repair or restore the Collateral or to pay sums secured by this Agreement, whether or not then due. The
ten (10) day period will begin when the notice is given. Unless Lender and Borrower otherwise agree in writing, any application of insurance proceeds to principal shall not extend or postpone the due date of any payments due under the
Promissory Note or change the amount of the payments. If the Collateral is acquired by Lender, Borrower’s right to any insurance policies and proceeds resulting from damage to the Collateral prior to the acquisition shall pass to Lender to the
extent of the sums secured by this Security Agreement immediately prior to the acquisition. 
 8. BUSINESS RECORDS. The Borrower will
at all times keep accurate and complete records of its business and upon default or threat of default, the Lender, or any of the Lender’s agents, shall have the right to call at the Borrower’s place of business during normal hours of
business to inspect the books, records, journals, orders, receipts, correspondence and other data relating to its business and the Collateral or to any other transaction between the parties hereto. 
 9. PROTECTION OF COLLATERAL. The Borrower shall keep the Collateral in good working order and repair and shall not waste or destroy the Collateral
or any part thereof. The Borrower shall not use the Collateral in violation of any statute or ordinance and the Lender or its agent shall have the right to examine and inspect the Collateral during normal business hours upon prior notice to Borrower
specifying the reasonable cause for the inspection. 
 10. PROTECTION OF LENDER’S RIGHTS IN THE COLLATERAL. If Borrower fails to
perform the covenants and agreements contained in this Security Agreement, or there is a legal proceeding that may significantly affect Lender’s rights in the Collateral (such as a proceeding in bankruptcy, probate, for condemnation or
forfeiture or to enforce laws or regulations), then Lender may do, and pay for, whatever is necessary to protect the value of the Collateral and Lender’s rights in the Collateral. Lender’s actions may include paying any sums secured by a
lien that has priority over this Security Agreement, appearing in court, paying reasonable attorneys’ fees and entering the location where the Collateral is to make repairs. Although Lender may take action under this paragraph, Lender does not
have to do so. Any amounts disbursed by Lender under this paragraph shall become additional debt of Borrower secured by this Security Agreement. Unless Borrower and Lender agree to other terms of payment, these amounts shall bear interest from the
date of disbursement at the Promissory Note rate and shall be payable, with interest, upon notice from Lender to Borrower requesting payment. 
 11. DEFAULT. Notwithstanding anything to the contrary herein, the Borrower shall be in default under this Security Agreement upon the occurrence of any of the following events or conditions: 
 (a) Default in the payment or performance of any term under any Promissory Note, obligations, covenants, liabilities or any other indebtedness of the
Borrower, referred to herein or secured hereby, specifically failure to pay when due any amount, principal or interest, payable on the loan made hereunder. 
  

 3 

 (b) Any warranty, representation or statement made or furnished to the Lender by or on behalf of the
Borrower proves to have been false in any material respect when made or furnished. 
 (c) Sale, transfer or assignment of a majority interest
in the Borrower without the prior written consent of the Lender. 
 (d) Sale, transfer or assignment of substantially all of the assets of the
Borrower without prior written consent of the Lender. 
 (e) Any levy, seizure or attachment of the Collateral. 
 (f) A change in the location of the Borrower’s business without the prior written consent of the Lender, which consent shall not be unreasonably
withheld. 
 (g) Dissolution, termination of existence, insolvency, business failure, appointment of a receiver for any part of the
Collateral, assignment for the benefit of creditors or the commencement of any proceeding under any bankruptcy or insolvency law by or against the Borrower or any guarantor or surety for the Borrower. 
 (h) Default under the business premises lease. 
 (i) Default under any obligation of Lender’s that has been assumed by Borrower. 
 (j) Failure to maintain adequate insurance as
provided in paragraph 7. 
 (k) Failure to pay all taxes as required by law. 
 (l) Waste or destruction of the Collateral or any part thereof. 
 (m) Any event of default hereunder shall also constitute a default under the terms of the Promissory Note. 
 12. REMEDIES. Upon the occurrence of any such event of default under this Agreement and prior to exercising the appropriate remedies, including, without limitation, the right of acceleration of the indebtedness, the Lender shall give
notice of default to the Borrower. The notice shall specify: (1) the default; (2) the action required to cure the default; (3) a date not less than ten (10) days from the date the notice is given to Borrower by which the default
must be cured; and (4) that failure to cure the default on or before the date specified in the notice may result in acceleration of the sums secured by this Security Agreement and sale of the Collateral. If Borrower fails to cure any default
prior to the expiration of the ten (10) day period, Lender may invoke any remedies permitted by this Security Agreement without further notice of demand on Borrower. 
  

 4 

 The Lender may take such action (without notice and without bond, in that Borrower herein expressly waives all rights
thereto prior to foreclosure and seizure by Lender) as it deems advisable to protect and enforce its rights against the Borrower and in and to the Collateral, including, but not limited to, the following actions, each of which may be pursued
concurrently or otherwise, at such time and in such order as the Lender may determine, in its sole discretion, without impairing or otherwise, affecting the other rights and remedies of the Lender under this Security Agreement or under any other
agreement between the Lender and the Borrower: 
 (a) Declare the Promissory Note to be forthwith due and payable, whereupon the same shall
become and be immediately due and payable, both as to principal and interest, without presentment and demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the Promissory Note to the
contrary notwithstanding. 
 (b) Receive and retain all the Collateral and proceeds and all other distributions of any kind upon any and all
of the Collateral. Borrower agrees to deliver the Collateral to Lender, and the Lender may without legal process, enter the business premises and take possession of all Collateral and proceeds found therein, without being guilty of trespass,
forcible entry or detainer. 
 (c) Exercise any and all rights and remedies afforded the Lender, as a Lender, in possession of Collateral or
otherwise, under any and all applicable provisions of law, all of which rights and remedies shall be cumulative, and not exclusive, to the extent permitted by law. All rights of the Lender hereunder shall inure to the benefit of Lender’s
successors and assigns and all obligations of the Borrower shall bind Borrower’s successors and assigns. 
 (d) Take such action as the
Lender may elect with respect to the foreclosure, sale, assignment and delivery of the whole, or from time to time any part of, the Collateral, including, without limitation, sell, assign, and deliver the Collateral at any broker’s board or at
any private sale in a commercially reasonable manner, or at public auction, after advertisement of the time and place of the sale, for cash, for credit or for other property, for immediate or future delivery, and for such price or prices as the
Lender shall determine, on commercially reasonable terms, and the Lender may bid for and purchase the whole or any part of the Collateral so sold free from any right or equity of redemption; to adjourn any such sale or cause the same to be adjourned
from time to time to a subsequent time and place announced at the time and place fixed for the sale; to carry out any agreement to sell any item or items of Collateral in accordance with the terms of such agreement, notwithstanding the fact that
after the Lender shall have entered into such an agreement, the Promissory Note may have been paid in full. 
 (e) The proceeds received by
the Lender from the disposition or sale of the Collateral shall be retained by the Lender as compensation for the use of the Collateral while in the Borrower’s possession and not as penalty and shall be applied: (1) to the cost, expenses
and reasonable attorney’s fees and expenses incurred by the Lender for the collection and for sale and delivery of the Collateral, and (2) to the outstanding principal and interest on the Promissory Note in such order as the Lender may
elect. If any proceeds remain after such application, such remainder shall be paid to the Borrower. Without such sale the fair market 

  

 5 

 
value of the property at the time of repossession may be credited upon the amount unpaid by Borrower. In any event, the Borrower agrees to pay the balance
forthwith as liquidated damages for the breach of this Agreement. 
 (f) Notice of any sale at public auction pursuant to paragraph
(d) shall be sufficient for all purposes if a written notice of any such sale is give to the Borrower by mailing a copy of a notice of such sale (naming the place, date and time thereof and a brief statement of the nature of the Collateral to
be sold) to the Borrower not less than five (5) days prior to any such sale and if a similar notice is published at least once, in a newspaper of general circulation published in Boston, Massachusetts not less than three (3) days nor more
than ten (10) days prior to such sale. The Borrower agrees that any disposition of Collateral made pursuant to the foregoing shall be deemed to have been made in a commercially reasonable manner, but the foregoing provision shall not be deemed
to limit the right of the Lender to dispose of any item of Collateral in any other manner provided in Article 9 of the Uniform Commercial Code. 
 13. BORROWER’S CLAIMS AGAINST REPOSSESSED COLLATERAL. If the Lender repossesses the Collateral, the Borrower agrees to send notice by registered mail to the Lender within twenty-four (24) hours after repossession if the
Borrower claims any articles not included herein or used as security hereby were contained in the Collateral at the time of repossession. The Borrower agrees that failure to do so shall be a waiver and bar to any subsequent claim therefore. The
Borrower hereby waives the right to remove any legal action, brought by the holder hereof, from the court originally acquiring jurisdiction. 
 14. ATTORNEY’S FEES. In the event Lender is required to take legal action to enforce any of the provisions of this Security Agreement, then in addition to such relief as shall be granted Lender, Lender shall also be entitled to
reasonable attorney’s fees. 
 15. NOTICES. Any notice to Borrower provided for in this Security Agreement shall be given by
delivering it or mailing it by first class mail unless applicable law requires use of another method. The notice shall be directed to the address of the Collateral or any other address Borrower designates by notice to Lender. Any notice to Lender
shall be given by first class mail to Lender’s address c/o Chief Executive Officer, 1099 Forest Lake Terrace, Niceville, FL 32578, or any other address Lender designates by notice to Borrower. Any notice provided for in this Security Agreement
shall be deemed to have been given to Borrower or Lender when given as provided in this paragraph. 
 16. TIME OF PERFORMANCE AND
WAIVER. In performing any act under this Security Agreement and the Promissory Note secured hereby, time shall be of the essence. The Lender’s extension of the time for payment for any indebtedness or the acceptance of only partial or
delinquent payments, or the failure of the Lender to enforce strict performance on the part of the Borrower of any covenant, promise or condition herein contained or contained in any other document evidencing the indebtedness owed the Lender by the
Borrower shall not operate as a waiver of the right of the Lender thereafter to require that the terms hereof or the terms of such other documents be strictly performed. 
  

 6 

 17. RIGHTS OF LENDER. The rights and remedies herein conferred upon the Lender shall be cumulative
and not alternative and shall be in addition to and not substitution of the rights and remedies conferred by the Uniform Commercial Code (UCC) of the State of Massachusetts. All rights of the Lender hereunder shall inure to the benefit of its
successors and assigns and all obligations of the Borrower shall bind its successors and assigns. 
 Until all sums secured by this Security Agreement have
been paid in full, Borrower, on demand of Lender, shall (or cause the same to be done) execute, acknowledge and deliver all such further instruments and papers, take all such further action as may be requested by Lender to effectuate the purposes
hereof, or to provide the rights and remedies of Lender contemplated hereby, or to avoid any breach hereof. 
 18. GOVERNING LAW;
SEVERABILITY. This Security Agreement shall be governed by the law of the State of Massachusetts. In the event that any provision or clause of this Security Agreement or the Promissory Note conflicts with applicable law, such conflict shall not
affect other provisions of this Security Agreement or the Promissory Note which can be given effect without the conflicting provision. To this end the provisions of this Security Agreement and the Promissory Note are declared to be severable.

 19. CONSTRUCTION AND SURVIVAL. This Agreement is the complete agreement between the parties and any contracts previously
executed between the parties, along with such other written or verbal representations or warranties as may have been made by either party, their broker, agents, or assigns, are merged into this Agreement and are extinguished, except as set forth
herein. The provisions and warranties contained in this Agreement shall survive the closing. 
 20. BINDING EFFECT. This Agreement
shall inure to the benefit of and be binding upon the Lender and the Borrower and their respective heirs, executors, administrators, successors and assigns and legal representatives, and shall survive the closing of this sale. 
 21. NUMBER AND GENDER. Whenever required by the context, the singular number shall include the plural and the masculine gender shall include the
feminine and the neuter. 
 22. HEADINGS. Headings of sections, subsections and paragraphs in this Agreement are for convenience only,
and neither limit nor amplify the provisions of this Agreement. 
 IN WITNESS WHEREOF, the parties have executed this Security Agreement on
the day and year first above written. 
 [SIGNATURES ON FOLLOWING PAGE] 
  

 7 

									
	  
 PRO-PHARMACEUTICALS, INC., a Nevada corporation
	 		 		 	 10X FUND, LP, a Delaware limited partnership
  
 10X Capital Management, LLC, General Partner, a Florida limited liability company

					
		 	 /s/ Anthony Squeglia
	 		 		 	 /s/ Rod Martin

	By:	 	Anthony Squeglia	 		 	By:	 	Rod Martin
	Its:	 	Chief Financial Officer	 		 	Title:	 	Managing Member

  

 8Escrow Agreement

 EXHIBIT 10.4 
 ESCROW AGREEMENT 
 THIS ESCROW AGREEMENT is made and entered into this 12th day of February,
2008, by and between Pro-Pharmaceuticals, Inc., a Nevada corporation (“Pharma”), 10X Fund, L.P., a Delaware limited partnership (“Fund”) and Investment Law Group of Gillett, Mottern & Walker, LLP
(“Escrow Agent”). 
 WITNESSETH: 
 WHEREAS, on February 12, 2009, Pharma and the Fund entered into a Securities Purchase Agreement (the “Purchase Agreement”), which provided for the issuance of shares of Series B-1
Convertible Preferred Stock and Series B-2 Convertible Preferred Stock (collectively, the “Preferred Stock”); 
 WHEREAS, the Preferred Stock is governed by a Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock of Pharma, as filed with the
Secretary of State of Nevada (the “Certificate of Designation”); 
 WHEREAS, Section 7(a) of the Certificate of
Designation provides that the Fund has the right to demand redemption of the Preferred Stock under certain circumstances, and Section 7(d) of the Certificate of Designation provides that Pharma’s obligation to redeem Preferred Stock will
convert to a promissory note secured by the assets of Pharma in the event Pharma does not satisfy a redemption obligation on its due date; 
 WHEREAS, Pharma and the Fund have executed a promissory note and security agreement (the “Note Documents”) pursuant to Section 7(d) of the Certificate of Designation, and have agreed that the Note Documents will be
held in escrow and released pursuant to this Agreement, and the Escrow Agent has agreed to serve as Escrow Agent in accordance with the terms and conditions set forth herein; and 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter contained, and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
 1. The Escrow Agent hereby acknowledges
receipt of the Note Documents executed by Pharma. 
 2. The Note Documents are to be held by the Escrow Agent in escrow and disposed of
pursuant to and strictly in accordance with the terms and conditions of this Agreement. The Escrow Agent undertakes to perform only such duties as are expressly set forth in this Agreement, and no implied duties or obligations of the Escrow Agent
shall be read into this Agreement. 

 3. The parties agree that the Escrow Agent shall dispose of the Note Documents as follows: 
 a) To the Fund, in the event an officer of the Fund certifies to the Escrow Agent that the Fund has exercised its right to require redemption of part or
all of its Preferred Stock pursuant to Section 7(a) of the Certificate of Designation, and Pharma has failed to pay the Redemption Price (as defined in the Certificate of Designation) by the Redemption Date (as defined in the Certificate of
Designation). 
 b) To Pharma, in the event an officer of Pharma certifies to the Escrow Agent that there are no further shares of Preferred
Stock outstanding because they have been redeemed for cash and/or converted into shares of common stock of Pharma pursuant to their terms. 
 c) Pursuant to joint written instructions signed by Pharma and the Fund. 
 4. The Escrow Agent shall not make any disbursements of
Note Documents except as expressly provided herein. 
 5. In the event the Escrow Agent is uncertain as to its duties or responsibilities
hereunder or either party shall challenge the validity, legality or authenticity of any notice sent by the other party to the Escrow Agent, the Escrow Agent may interplead the Note Documents in the state court of Fulton County, State of Georgia, and
Pharma and the Fund consent to jurisdiction and venue in such court for purposes of an interpleader action. The losing party in such proceeding shall indemnify and hold harmless the Escrow Agent from all costs and expenses, including reasonable
attorney’s fees associated with the proceeding. Escrow Agent may act in reliance upon any writing or instrument or signature which it in good faith believes to be genuine and may assume that any person purporting to give any writing, notice,
advice, or instruction in connection with the provisions hereof has been duly authorized to do so. Escrow Agent shall not be liable in any manner for the sufficiency or correctness as to form, manner of execution or validity of any instrument
deposited in this escrow nor as to the identity, authority or right of any persons executing the same, and its duties hereunder shall be limited to the safekeeping of the Note Documents and for the disposition of same in accordance with this
Agreement. Escrow Agent hereby executes this Agreement for the sole and exclusive purpose of evidencing its Agreement of the provisions hereof. 
 6. Pharma and the Fund agree to indemnify and hold the Escrow Agent harmless from any and all claims, liabilities, losses, actions, suits or proceedings at law or in equity, or any other expense, fees, or charges of any character or nature,
which it may incur or with which it may be threatened by reason of its acting as Escrow Agent under this Agreement, and in connection therewith, to indemnify the Escrow Agent against any and all expenses, including reasonable attorney’s fees
and the cost of defending any action, suit or proceeding or resisting any claim. 
 7. The Escrow Agent may consult with counsel of its own
choice and shall have full and complete authorization and protection for any action taken or suffered by it and hereunder in good faith and in accordance with the opinion of such counsel. The Escrow Agent shall otherwise not be liable for any
mistakes of fact or error in judgment, or for any acts or omissions of any kind unless caused by its willful misconduct or gross negligence. 
  

 2 

 8. The parties agree that Pharma shall be responsible for the fees and expenses of the Escrow Agent for
serving as Escrow Agent hereunder, which shall be billed at the Escrow Agent’s normal hourly rate. 
 9. The provisions of this
Agreement may not be amended, supplemented, waived or changed orally, but only by a writing signed by the party as to whom enforcement of any such amendment, modification, supplement or waiver is sought and making specific reference to this
Agreement. 
 10. All notices required or permitted hereunder, and under any instrument delivered pursuant hereto, shall be given in writing,
and shall be deemed to have been given and received upon the earlier to occur of: (a) the actual receipt of any such notice by the intended recipient; and (b) the third business day following deposit of any such notice enclosed in a
wrapper with postage prepaid, properly addressed to the intended recipient at its address set forth below, as a certified item, return receipt requested, in an official depository of and under the care and custody of the United States Postal
Service. The parties’ address for notice shall be as set forth in the first paragraph of this Agreement. Any party hereto may change its address for notice set forth herein by giving the other parties at least 10 days advance written notice of
such change of address. All notices to the Escrow Agent shall be sent to: 
 Investment Law Group of 
 Gillett, Mottern & Walker, LLP 
 1230
Peachtree Street, N.E. 
 Suite 2445 
 Atlanta, Georgia 30309 
 Phone: 404-607-6933 
 Fax: 404-607-6942 
 Email: bmottern@investmentlawgroup.com 
 12. Escrow Agent shall have no duties or responsibilities other than those expressly set forth herein. Escrow Agent shall not be liable for any action
taken or omitted by it, or any action suffered by it, except for gross negligence or willful misconduct. The Escrow Agent shall not be bound by any notice or demand unless evidenced by a writing delivered to Escrow Agent signed by the proper party
or parties. 
 13. This Agreement contains the entire understanding between and among the parties hereto with respect to the subject matter
hereof, and shall be binding upon and inure to the benefit of such parties, and their respective heirs, successors in interest and legal representatives. 
 14. This Agreement is governed by, and is to be construed in accordance with, the laws of the State of Georgia. 
  

 3 

 This Agreement may be executed in counterpart. 
  

									
	PHARMA:	 		 	FUND:
			
	Pro-Pharmaceuticals, Inc., a Nevada corporation	 		 	10X FUND, LP, a Delaware limited partnership
					
		 		 		 		 	10X Capital Management, LLC, General Partner
					
		 	/s/ Anthony Squeglia	 		 		 	/s/ James C. Czirr
	 	 		 	 
	By:	 	Anthony Squeglia	 		 	By:	 	James C. Czirr
		 		 		 	Title:	 	Managing Partners
					
	Address:	 	 7 Wells Avenue
 Newton, MA 02453
	 		 	Address:	 	 1099 Forest Lake Terrace
 Niceville, FL
32578

	Phone:	 	(617) 559-0033	 		 	Phone:	 	(850) 502-7659
	Fax:	 	(617) 928-3450	 		 	Fax:	 	(850) 678-8722
	Email:	 	squeglia@pro-pharmaceuticals.com	 		 	Email:	 	jimczirr52@gmail.com
				
	ESCROW AGENT:	 		 		 	
				
	INVESTMENT LAW GROUP OF GILLETT, MOTTERN & WALKER, LLP	 		 		 	
					
		 	/s/ Robert J. Mottern	 		 		 	
	 	 		 		 	
	By:	 	Robert J. Mottern, Vice President	 		 		 	

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}]]